{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK\nInhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed\/Refractory Peripheral T-cell Lymphoma Not Otherwise\nSpecified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-open-label-study-to-investigate-the-efficacy-and-safety-of-itkinhibitor-soquelitinib-versus-physicians-choice-standard-of-care-treatment-selected-single-agent-in-participants\/#breadcrumbitem"}]}